Skip to main content

Table 3 Worst toxicity per patient (n = 50)

From: Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

Toxicity

Worst NCI – CTC grade Number of patients (%)

 

0

1

2

3

4

5

Anemia

15 (30%)

8 (16%)

19 (38%)

8 (16%)

-

-

Leukopenia

12 (24%)

11 (22%)

19 (38%)

6 (12%)

2 (4%)

-

Neutropenia

11 (22%)

5 (10%)

11 (22%)

18 (36%)

5 (10%)

-

Febrile neutropenia

50 (100%)

-

-

-

-

-

Neutropenic infection

50 (100%)

-

-

-

-

-

Non neutrop. infection

49 (98%)

-

1 (2%)

-

-

-

Platelets

25 (50%)

7 (14%)

5 (10%)

11 (22%)

2 (4%)

-

Platelet transfusion

50 (100%)

-

-

-

-

-

RBC transfusion

47 (94%)

-

-

3 (6%)

-

-

Allergy

45 (90%)

2 (4%)

1 (2%)

2 (4%)

-

-

Bleeding

50 (100%)

-

-

-

-

-

Fatigue

27 (54%)

13 (26%)

10 (20%)

-

-

-

Heart rhythm

48 (96%)

2 (4%)

-

-

-

-

Cardiovascular

48 (96%)

1 (2%)

-

1 (2%)

-

-

Pulmonary

47 (94%)

3 (6%)

-

-

-

-

Fever

48 (96%)

2 (4%)

-

-

-

-

Weight loss

48 (96%)

1 (2%)

1 (2%)

-

-

-

Hair loss

40 (80%)

7 (14%)

3 (6%)

-

-

-

Local reaction

49 (98%)

1 (2%)

-

-

-

-

Skin (including PPE)

43 (86%)

5 (10%)

1 (2%)

1 (2%)

-

-

Anorexia

44 (88%)

4 (8%)

2 (4%)

-

-

-

Constipation

35 (70%)

9 (18%)

6 (12%)

-

-

-

Diarrhoea

49 (98%)

1 (25)

-

-

-

-

Nausea

27 (54%)

16 (32%)

6 (12%)

1 (2%)

-

-

Vomiting

38 (76%)

8 (16%)

2 (4%)

2 (4%)

-

-

Stomatitis

42 (84%)

4 (8%)

4 (8%)

-

-

-

Liver

44 (88%)

3 (6%)

2 (4%)

1 (2%)

-

-

Neuropathy

49 (98%)

1 (2%)

-

-

-

-

Kidney

49 (98%)

1 (2%)

-

-

-

-

Other

47 (94%)

2 (4%)*

-

1 (2%)**

-

-

  1. RBC = red blood cell; PPE = palmar-plantar erythrodysesthesia
  2. *hyperglycemia (1 patient); epigastric pain (1 patient); ** abdominal pain